Tunable endogenous protein degradation

Abstract

The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.

1 . A composition comprising an isolated cell and a heterobifunctional compound, wherein the isolated cell comprises:
 a nucleic acid sequence encoding a heterobifunctional compound targeting protein (dTAG) that has the amino acid sequence of SEQ ID NO: 2, 3, or 9, wherein said dTAG is capable of being bound by a heterobifunctional compound selected from dFKBP-6-dFKBP-13, dBET1-dBET18, dBromo1-dBromo34, and dHalo1-dHalo2, and a nucleic acid sequence encoding a CRISPR RNA-guided endonuclease;   wherein the CRISPR RNA-guided endonuclease, upon being expressed, acts to genomically integrate the nucleic acid encoding the heterobifunctional compound targeting protein;   wherein the nucleic acid sequence encoding the dTAG is integrated genomically in-frame in a 5′ or 3′ orientation with a nucleic acid sequence of a gene encoding an endogenous protein;   wherein expression of the gene encoding the endogenous protein produces an endogenous protein-dTAG hybrid protein;   wherein the heterobifunctional compound binds to a) the endogenous protein-dTAG hybrid protein through the dTAG and b) a ubiquitin ligase in a manner that brings the endogenous protein-dTAG hybrid protein into proximity of the ubiquitin ligase;   wherein the endogenous protein-dTAG hybrid protein is ubiquitinated and then degraded by a proteasome; and   the heterobifunctional compound which is selected from dFKBP-6-dFKBP-13, dBET1-dBET18, dBromo1-dBromo34, and dHalo1-dHalo2.   
     
     
         2 . The composition of  claim 1 , wherein the cell is a human cell. 
     
     
         3 . The composition of  claim 1 , wherein the heterobifunctional compound targeting protein (dTAG) that has the amino acid sequence of SEQ ID NO: 2. 
     
     
         4 . The composition of  claim 1 , wherein the nucleic acid sequence encoding the heterobifunctional compound targeting protein is inserted in frame with a gene encoding an endogenous protein associated with a disease that is a result of a gain of function mutation, amplification or increased expression, a monogenetic disease, a proteopathy, or a combination thereof. 
     
     
         5 . The composition of  claim 1 , wherein the CRISPR RNA-guided endonuclease is selected from Cas1, Cas IB, Cas2, Cas3, Cas4, Cas5, Cash, Cas7, Cas8, Cas9, Cas10, Csy1, Csy2, Csy2, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cpf1. 
     
     
         6 . The composition of  claim 1 , wherein the heterobifunctional compound targeting protein does not substantially interfere with the function of the endogenously expressed protein. 
     
     
         7 .- 13 . (canceled) 
     
     
         14 . A method of reducing gene overexpression in a subject comprising:
 transforming one or more cells of the subject with a nucleic acid sequence encoding a heterobifunctional compound targeting protein (dTAG), that has the amino acid sequence of SEQ ID NO: 2, 3, or 9, wherein said dTAG is capable of being bound by a heterobifunctional compound selected from dFKBP-6-dFKBP-13, dBET1-dBET18, dBromo1-dBromo34, and dHalo1-dHalo2;   wherein the nucleic acid sequence is integrated genomically in-frame in a 5′ or 3′ orientation with a nucleic acid sequence of an endogenous protein associated with a disease due to overexpression of the endogenous protein;   wherein insertion of the nucleic acid encoding the dTAG into the genomic sequence results in an endogenous protein-dTAG hybrid protein upon expression; and   administering to the subject a heterobifunctional compound;   wherein the heterobifunctional compound binds to a) the endogenous protein-dTAG hybrid protein through the dTAG and b) a ubiquitin ligase in a manner that brings the endogenous protein-dTAG hybrid into proximity of the ubiquitin ligase, wherein the endogenous protein-dTAG hybrid protein is ubiquitinated and then degraded by a proteasome; and   wherein the heterobifunctional compound is selected from dFKBP-6-dFKBP-13, dBET1-dBET18, dBromo1-dBromo34, and dHalo1-dHalo2.   
     
     
         15 . The method of  claim 14 , wherein the subject is a human. 
     
     
         16 . The method of  claim 14 , wherein the heterobifunctional compound targeting protein (dTAG) that has the amino acid sequence of SEQ ID NO: 2. 
     
     
         17 . The method of  claim 14 , wherein the nucleic acid sequence encoding the heterobifunctional compound targeting protein is inserted in frame with a gene encoding an endogenous protein associated with a disease that is a result of a gain of function mutation, amplification or increased expression, a monogenetic disease, a proteopathy, or a combination thereof. 
     
     
         18 . The method of  claim 14 , further comprising a nucleic acid sequence encoding a CRISPR RNA-guided endonuclease, wherein the CRISPR RNA-guided endonuclease, upon being expressed, acts to genomically integrate the nucleic acid sequence encoding the heterobifunctional compound targeting protein. 
     
     
         19 . The method of  claim 18 , wherein the CRISPR RNA-guided endonuclease is selected from Cas1, Cas IB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9, Cas10, Csy1, Csy2, Csy2, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cpf1. 
     
     
         20 . The method of  claim 14 , wherein the heterobifunctional compound targeting protein does not substantially interfere with the function of the endogenously expressed protein. 
     
     
         21 . An isolated cell, comprising:
 a nucleic acid sequence encoding a heterobifunctional compound targeting protein (dTAG) that has the amino acid sequence of SEQ ID NO: 2, 3, or 9, wherein said dTAG is capable of being bound by a heterobifunctional compound selected from dFKBP-6-dFKBP-13, dBET1-dBET18, dBromo1-dBromo34, and dHalo1-dHalo2, and a nucleic acid sequence encoding a CRISPR RNA-guided endonuclease;   wherein the CRISPR RNA-guided endonuclease, upon being expressed, acts to genomically integrate the nucleic acid encoding the heterobifunctional compound targeting protein;   wherein the nucleic acid sequence encoding the dTAG is integrated genomically in-frame in a 5′ or 3′ orientation with a nucleic acid sequence of a gene encoding an endogenous protein;   wherein expression of the gene encoding the endogenous protein produces an endogenous protein-dTAG hybrid protein;   wherein the heterobifunctional compound binds to a) the endogenous protein-dTAG hybrid protein through the dTAG and b) a ubiquitin ligase in a manner that brings the endogenous protein-dTAG hybrid protein into proximity of the ubiquitin ligase; and   wherein the endogenous protein-dTAG hybrid protein is ubiquitinated and then degraded by a proteasome,   wherein the isolated cell further comprises the heterobifunctional compound; and   wherein the heterobifunctional compound is selected from dFKBP-6-dFKBP-13, dBET1-dBET18, dBromo1-dBromo34, and dHalo1-dHalo2.